ZymoGenetics, Inc. (NASDAQ: ZGEN), today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE